• Revenue up 61.2% to $36.9 million, driven by acquisitions and organic growth
• EBITDA up 149.9% to $5.2 million, exceeding guidance
• Net Profit After Tax up 150.1% to $2.9 million
• Unfilled Contracted Revenue stands at $50.2 million

Austco Healthcare Limited has reported its results for the half-year ended 31 December 2024, delivering record revenue, earnings, and profitability. Revenue from customers increased by 61.2% to $36.9 million, driven by the successful integration of two recent acquisitions (Teknocorp and Amentco) and continued organic growth in Asia and North America. The company's software and recurring revenue also grew by 15% to $4.6 million, now comprising 19.4% of the Unfilled Contracted Revenue book. Gross margins remained healthy at 51.1%, despite the impact of the lower-margin acquired businesses. EBITDA surged 149.9% to $5.2 million, exceeding the company's guidance, while Net Profit After Tax increased by 150.1% to $2.9 million. Austco's cash position remained strong at $14.9 million, with the company remaining debt-free. The Unfilled Contracted Revenue book stood at $50.2 million as of 10 February 2025, providing good visibility on future earnings. The company continued to invest in research and development, spending $2.3 million in the period.

The company expects revenue and EBITDA for the full 2025 financial year to be at the top end of the guidance range provided in the 18 December 2024 trading update.

Austco Healthcare remains focused on driving organic growth, particularly in its software and recurring revenue streams, while continuing to pursue strategic acquisitions to further expand its market presence and capabilities.